Benbrook Research Group

Click on the blue text below for more information

Doris M. Benbrook, PhD, Principal Investigator

OK-1 (SHetA2) Drug Facebook Page

Interview

 

Faculty

 

 

 

 

 

 

 

 

 

 

 

 

Vishal Chandra, PhD

Assistant Professor of Research

Endometrial Cancer Prevention and Treatment

Bethany Hannafon, PhD

Assistant Professor of Research

 Exosome and miRNA Breast Cancer Biomarkers

Satish Kumar Ramraj, PhD

Assistant Professor of Research

Prevention of Fallopian Tube Carcinogenesis to Ovarian Cancer

Postdoctoral Fellows

 

 

 

 

 

 

 

 

 

 

 

 

 

Rajani Rai, PhD

Prevention of Tobacco Carcinogenesis

 

Sugantha Priya Elayapillai, PhD

Repurposing Mebendazole for Ovarian Cancer

 

 

 

 

 

 

 

 

 

 

 

 

 

Tara Castellano, MD

Aspirin Prevention of Ovarian Cancer

Graduate Students

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amy Bosley, BA

Pathology Department

Combination Drug Therapy for Cervical Cancer

Zitha Isingizwe, BS

Pharmaceutical Sciences Department

How to prevent platelet promotion of ovarian cancer

Technicians

 

 

 

Kat Benbrook

 

 

 

Matthew Bruns, BS

 

 

 

Shelby Jewell, BS

 

 

 

 

 

 

 

Caitlin Raub

 

 

 

 

 

Current Research Projects

 

How does ovarian cancer develop from the fallopian tube and how can it be prevented?

 

Recent Publications:

Benbrook, D. M., Janakiram, N. B., Chandra, V.*, Pathurib, G., Madk, V., Stratton, N. C., Masamha, C. P, Farnsworth, C. N., Garcia-Contreras, L., Hatipoglu, M. K., Lightfoot, S., Rao, C. V. (2018). Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational New Drugs, 36(4), 561-570. PMID: 29273857. DOI: 10.1007/s10637-017-0550-0

Ramraj, S. K., Smith, K. M., Janakiram, N. B., Toal, C., Raman, A., Benbrook, D. M. (2018). Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue & cell, 52, 57-64. PMID: 29857829. DOI: 10.1016/j.tice.2018.04.001

 

Current Funding:

 

Benbrook, D. M. (Principal Investigator), 40% Effort, Rao, C. (Co-Investigator), Janakiram, N. (Co-Investigator),

Garcia-Contreras, L. (Co-Investigator), Woo, S. (Co-Investigator), Zuna, R. (Co-Investigator), Crouse, E. (Co-Investigator),

Ovarian Cancer Chemoprevention

Peer-reviewed Nationally-funded Research Grant, Sponsored by National Cancer Institute, Federal  Grant/Contract Number: R01 CA196200/C31042101
Current Funding (Total Cost per Year): $503,992

Total Direct Costs Per Year: $340,535
July 1, 2015 - June 30, 2020

 

Benbrook, D. M. (Principal Investigator)

 cGMP NSC 721689 Production for IRB-approved and NCI-funded Clinical Trials

Sponsored by NCI PREVENT, Federal
Grant/Contract Number: 721689
February 10, 2015 - Present

 

How do HPV and tobacco cause cervical cancer and how can it be prevented and treated?

Current Funding:

 

Benbrook, D. M. (Principal Investigator), 30% Effort, Rao, C. (Co-Principal Investigator), Zuna, R. (Co-Investigator),

Garcia-Contreras, L. (Co-Principal Investigator), Woo, S. (Co-Principal Investigator), Zhao, D. (Co-Investigator),

Frumovitz, M. (Co-Principal Investigator), Coleman, R. (Co-Principal Investigator),

Targeting HPV Consequences in a Cervical Cancer Clinical Trial Peer-reviewed, federally-funded research grant, Sponsored by NIH/NCI, Federal Grant/Contract Number: R01 CA200126/C3111201
Current Funding (Total Cost per Year): $595,072
Total Direct Costs: $425,303.00

June 1, 2016 - May 31, 2022


 

How do estrogen & obesity cause endometrial cancer and how can it be prevented & treated?

Recent Publications:

Chandra, V., Kim, J. J., Benbrook, D. M., Dwivedi, A., Rai, R.#, Gyeongbuk, G. (2016). Therapeutic options for management of endometrial hyperplasia: An update. J Gynecol Oncol, 27(1). PMID: 26463434. DOI: 10.3802/jgo.2016.27.e8

 

Current Funding:

Benbrook, D. M. (Project Director), Chandra, V. (Co-Project Director), Rai, R. (Co-Project Director), Rao, C. (Principal Investigator), Chemoprevention of Endometrial Hyperplasia and Its Transition to Endometrial Cancer with NSC 721689

Sponsored by NCI PREVENT Program, Federal Direct Total Costs $713,988
June 16, 2017 - June 14, 2019

 

Can glycoprotein levels in primary tumors predict cervical cancer lymph node metastases?

Clinical Trial:

Benbrook, D. M. (Study Co-Chair), Gold, M. A. (Study Chair), Cummings, R. (Study Co-Chair), Rodgers, W. (Study Co-Chair)

Comparison of Glycoprotein Expression and T-Synthase Function in Primary versus Metastatic Tumors

Sponsored by Gynecologic Oncology Group, Foundation Grant/Contract Number: GOG - 0221
April 13, 2007 - August 24, 2017